查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1973924

抗肥胖藥物市場分析及至2035年預測：類型、產品、服務、技術、組件、應用、劑型、最終用戶、設備、模式

Anti Obesity Drugs Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, Form, End User, Device, Mode
出版日期: | 出版商: Global Insight Services | 英文 331 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計到2034年，抗肥胖藥物市場規模將從2024年的172億美元成長至1,641億美元，年複合成長率約為25.3%。該市場涵蓋透過抑制食慾、促進新陳代謝和抑制脂肪吸收來幫助減重的藥物。肥胖率上升、生活方式改變和健康意識增強是推動該市場成長的主要因素。注重療效、安全性和減少副作用的創新，以及監管部門的核准，正在塑造市場動態。策略合作和研發投入對於解決全球肥胖問題至關重要，並蘊藏著巨大的成長機會。

受肥胖率上升和人們對健康風險意識增強的推動，抗肥胖藥物市場正經歷顯著成長。藥物治療領域佔主導地位，其中GLP-1受體促效劑因其在體重管理和代謝改善方面的有效性主導。具有協同效應並能改善患者預後的複方藥物緊跟其後。處方藥細分市場表現優於非處方藥，這得益於醫師的推薦和已證實的臨床結果。腸道菌群調節劑等新興療法作為新的減重方法正受到關注。針對兒童肥胖的兒童抗肥胖藥物市場也預計將成長。藥物遞送系統的創新，包括口服和注射劑型，正在提高患者依從性並擴大市場吸引力。隨著基於基因譜的個人化治療策略的重要性日益凸顯，個人化醫療也變得愈發重要。製藥業持續的研發投入和策略合作正在推動市場擴張。

市場區隔
類型 處方藥、非處方藥、草藥補充劑
產品 食慾抑制劑、代謝促進劑、脂肪吸收抑制劑、複方藥物
服務 諮詢服務、體重管理計劃、生活方式指導
科技 藥理基因體學、奈米技術、生物技術
成分 活性成分、添加劑
目的 慢性肥胖、體重管理
形式 片劑、膠囊、液體、注射劑
最終用戶 醫院、診所、居家醫療機構、健康中心
裝置 醫療設備、穿戴式裝置
模式 口服，注射

市場概況：

隨著多家公司推出創新產品，抗肥胖藥物市場正經歷市場佔有率的動態變化。定價策略依然競爭激烈，反映出市場對有效體重管理方案的需求。新產品的推出著重於先進的製劑技術和給藥機制，從而提升了消費者的興趣。市場正朝著個人化醫療的方向發展，各公司加大研發投入，致力於提供個人化解決方案。競爭基準分析凸顯了主要企業利用策略聯盟和收購來鞏固其市場地位的主導地位。監管影響顯著，嚴格的指導方針影響醫藥品認證過程。然而，這些法規也有助於確保藥物的高安全性和有效性標準，並增強消費者信心。該市場的特點是技術快速發展，人工智慧和數據分析在藥物研發中發揮著至關重要的作用。在全球範圍內，北美和歐洲主導地位，而新興市場則展現出尚未開發的成長潛力，不同地區的市場接受度也存在差異。

主要趨勢和促進因素：

受肥胖率上升和人們對健康風險意識增強的推動，抗肥胖藥物市場正經歷強勁成長。藥物研發領域的技術創新使得療效更佳、副作用更少的治療方法成為可能，從而促進了市場擴張。生活方式的改變和久坐不動的生活方式加劇了肥胖的流行，因此需要藥物干預。政府推行的促進體重管理和肥胖預防的措施和醫療保健政策進一步推動了市場發展。隨著人們對個人化醫療的需求日益成長，標靶治療的創新不斷進步，提高了藥物療效和患者預後。此外，數位健康工具的整合有助於提高病患的用藥依從性和監測效果，進而提高治療成功率。在新興市場，不斷完善的醫療基礎設施和不斷成長的可支配收入創造了盈利的市場機會。製藥公司之間的策略聯盟和合作研究正在加速研發和新型抗肥胖藥物的上市。隨著人們對肥胖相關併發症的認知不斷提高，預計該市場將繼續成長，並專注於提供全面、以患者為中心的解決方案。

壓制與挑戰：

目前，抗肥胖藥物市場面臨許多重大限制與挑戰。首要限制因素是嚴格的法規環境，繁瑣的核准流程延緩了新藥上市。這種監管複雜性往往導致製藥公司成本增加、研發週期延長。另一個挑戰是藥物研發和商業化成本高昂，這會阻礙投資和創新。許多公司在嘗試將新型抗肥胖解決方案推向市場時都面臨資金障礙。此外，持續存在的社會歧視削弱了市場潛力，導致患者治療順從性降低，不願尋求治療。另外，現有抗肥胖藥物療效有限且副作用較大，也阻礙了市場發展，往往無法滿足患者和醫生的期望。最後，生活方式和飲食療法作為第一線治療方案的日益普及進一步降低了對藥物治療的需求，從而影響了市場成長。

目錄

第1章摘要整理

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 處方藥
    • 非處方藥
    • 草藥補充劑
  • 市場規模及預測：依產品分類
    • 食慾抑制劑
    • 代謝加速器
    • 脂質吸收抑制劑
    • 複方藥物
  • 市場規模及預測：依服務分類
    • 諮詢服務
    • 體重管理計劃
    • 生活方式指導
  • 市場規模及預測：依技術分類
    • 藥物基因體學
    • 奈米科技
    • 生物技術
  • 市場規模及預測：依組件分類
    • 醫藥原料藥
    • 添加劑
  • 市場規模及預測：依應用領域分類
    • 慢性肥胖
    • 體重管理
  • 市場規模及預測：依類型
    • 藥片
    • 膠囊
    • 液體
    • 注射藥物
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診所
    • 居家醫療環境
    • 健康中心
  • 市場規模及預測：依設備分類
    • 醫療設備
    • 穿戴式裝置
  • 市場規模及預測：按模式
    • 口服
    • 注射藥物

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Orexigen Therapeutics
  • Vivus
  • Arena Pharmaceuticals
  • Zafgen
  • Rhythm Pharmaceuticals
  • Novo Nordisk
  • Gelesis
  • Eisai Co Ltd
  • Alizyme Therapeutics
  • NeuroSearch
  • Sorrento Therapeutics
  • Amgen
  • Allergan
  • Saniona
  • 8i Ventures

第9章 關於我們

簡介目錄
Product Code: GIS33623

Anti Obesity Drugs Market is anticipated to expand from $17.2 billion in 2024 to $164.1 billion by 2034, growing at a CAGR of approximately 25.3%. The Anti Obesity Drugs Market encompasses pharmaceuticals designed to aid weight loss by reducing appetite, increasing metabolism, or inhibiting fat absorption. This market is driven by rising obesity rates, lifestyle changes, and increasing health awareness. Innovations focus on efficacy, safety, and minimal side effects, with regulatory approvals shaping market dynamics. Strategic partnerships and research investments are pivotal in addressing the global obesity epidemic, offering significant growth opportunities.

The Anti-Obesity Drugs Market is experiencing significant growth, propelled by rising obesity rates and increased awareness of health risks. The pharmacotherapy segment dominates, with GLP-1 receptor agonists leading due to their efficacy in weight management and metabolic improvement. Following closely are combination drugs, which offer synergistic effects and enhanced patient outcomes. The prescription drugs sub-segment outperforms over-the-counter options, driven by physician recommendations and proven clinical results. Emerging therapies, such as gut microbiome modulators, are gaining attention for their novel approach to weight loss. The pediatric anti-obesity drugs segment is also expected to grow, addressing childhood obesity concerns. Innovations in drug delivery systems, including oral and injectable formulations, enhance patient compliance and broaden market appeal. Personalized medicine is becoming increasingly relevant, with genetic profiling guiding tailored therapeutic strategies. The market is poised for expansion, supported by ongoing research and development efforts and strategic partnerships in the pharmaceutical industry.

Market Segmentation
TypePrescription Drugs, Over-the-Counter Drugs, Herbal Supplements
ProductAppetite Suppressants, Metabolic Enhancers, Fat Absorption Inhibitors, Combination Drugs
ServicesConsultation Services, Weight Management Programs, Lifestyle Counseling
TechnologyPharmacogenomics, Nanotechnology, Biotechnology
ComponentActive Pharmaceutical Ingredients, Excipients
ApplicationChronic Obesity, Weight Management
FormTablets, Capsules, Liquid, Injectables
End UserHospitals, Clinics, Home Care Settings, Wellness Centers
DeviceMedical Devices, Wearable Devices
ModeOral, Injectable

Market Snapshot:

The Anti Obesity Drugs Market is experiencing a dynamic shift in market share, with several companies introducing innovative products. Pricing strategies remain competitive, reflecting the demand for effective weight management solutions. New product launches are focusing on advanced formulations and delivery mechanisms, contributing to heightened consumer interest. The market is witnessing a trend towards personalized medicine, with companies investing in research and development to offer tailored solutions. Competition benchmarking highlights the dominance of key players who are leveraging strategic partnerships and acquisitions to enhance their market position. Regulatory influences are significant, with stringent guidelines affecting drug approval processes. However, these regulations also ensure high safety and efficacy standards, fostering consumer trust. The market is characterized by rapid technological advancements, with AI and data analytics playing crucial roles in drug development. The global landscape shows varying adoption rates, with North America and Europe leading, while emerging markets present untapped potential for growth.

Geographical Overview:

The anti-obesity drugs market is witnessing notable growth across diverse regions, each exhibiting unique characteristics. North America dominates the market, propelled by escalating obesity rates and robust healthcare infrastructure. The region's focus on innovative drug development and supportive regulatory frameworks further bolsters its market leadership. Europe follows, driven by increasing health consciousness and government initiatives to curb obesity prevalence. The region benefits from a strong pharmaceutical industry and collaborative research efforts. In the Asia Pacific, the market is expanding rapidly, driven by rising obesity rates and increasing healthcare expenditure. Countries like China and India are emerging as significant growth pockets due to their large population base and improving healthcare access. Latin America and the Middle East & Africa are also witnessing growth, albeit at a slower pace. In these regions, rising awareness and government initiatives to combat obesity are creating new opportunities for market expansion.

Key Trends and Drivers:

The Anti-Obesity Drugs Market is experiencing robust growth fueled by rising obesity rates and increasing awareness of health risks. Technological advancements in drug development have led to more effective treatments with fewer side effects, driving market expansion. Lifestyle changes and sedentary habits are contributing to higher obesity prevalence, necessitating pharmaceutical interventions. Government initiatives and healthcare policies promoting weight management and obesity prevention are further propelling the market. The demand for personalized medicine is encouraging innovation in targeted therapies, enhancing drug efficacy and patient outcomes. Additionally, the integration of digital health tools is supporting patient adherence and monitoring, bolstering treatment success. Emerging markets present lucrative opportunities due to growing healthcare infrastructure and rising disposable incomes. Strategic partnerships and collaborations among pharmaceutical companies are fostering research and development, accelerating the introduction of novel anti-obesity drugs. As awareness of obesity-related complications increases, the market is poised for sustained growth, with a focus on holistic and patient-centric solutions.

Restraints and Challenges:

The Anti-Obesity Drugs Market is currently confronted with several significant restraints and challenges. A primary restraint is the stringent regulatory environment, which imposes rigorous approval processes, delaying the introduction of new drugs to the market. This regulatory complexity often results in increased costs and extended timelines for pharmaceutical companies. Another challenge is the high cost of drug development and commercialization, which can deter investment and innovation. Many companies face financial barriers when attempting to bring novel anti-obesity solutions to market. Additionally, there is a persistent stigma associated with obesity, leading to low patient adherence and reluctance to seek treatment, which undermines market potential. Moreover, the market is hindered by the limited efficacy and side effects of current anti-obesity medications, which often fail to meet patient and physician expectations. Lastly, the growing emphasis on lifestyle and dietary interventions as first-line treatments further diminishes the demand for pharmacological solutions, impacting market growth.

Key Players:

Orexigen Therapeutics, Vivus, Arena Pharmaceuticals, Zafgen, Rhythm Pharmaceuticals, Novo Nordisk, Gelesis, Eisai Co Ltd, Alizyme Therapeutics, NeuroSearch, Sorrento Therapeutics, Amgen, Allergan, Saniona, 8i Ventures

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by Form
  • 2.8 Key Market Highlights by End User
  • 2.9 Key Market Highlights by Device
  • 2.10 Key Market Highlights by Mode

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Prescription Drugs
    • 4.1.2 Over-the-Counter Drugs
    • 4.1.3 Herbal Supplements
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Appetite Suppressants
    • 4.2.2 Metabolic Enhancers
    • 4.2.3 Fat Absorption Inhibitors
    • 4.2.4 Combination Drugs
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Consultation Services
    • 4.3.2 Weight Management Programs
    • 4.3.3 Lifestyle Counseling
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Pharmacogenomics
    • 4.4.2 Nanotechnology
    • 4.4.3 Biotechnology
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 Active Pharmaceutical Ingredients
    • 4.5.2 Excipients
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Chronic Obesity
    • 4.6.2 Weight Management
  • 4.7 Market Size & Forecast by Form (2020-2035)
    • 4.7.1 Tablets
    • 4.7.2 Capsules
    • 4.7.3 Liquid
    • 4.7.4 Injectables
  • 4.8 Market Size & Forecast by End User (2020-2035)
    • 4.8.1 Hospitals
    • 4.8.2 Clinics
    • 4.8.3 Home Care Settings
    • 4.8.4 Wellness Centers
  • 4.9 Market Size & Forecast by Device (2020-2035)
    • 4.9.1 Medical Devices
    • 4.9.2 Wearable Devices
  • 4.10 Market Size & Forecast by Mode (2020-2035)
    • 4.10.1 Oral
    • 4.10.2 Injectable

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 Form
      • 5.2.1.8 End User
      • 5.2.1.9 Device
      • 5.2.1.10 Mode
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 Form
      • 5.2.2.8 End User
      • 5.2.2.9 Device
      • 5.2.2.10 Mode
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 Form
      • 5.2.3.8 End User
      • 5.2.3.9 Device
      • 5.2.3.10 Mode
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 Form
      • 5.3.1.8 End User
      • 5.3.1.9 Device
      • 5.3.1.10 Mode
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 Form
      • 5.3.2.8 End User
      • 5.3.2.9 Device
      • 5.3.2.10 Mode
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 Form
      • 5.3.3.8 End User
      • 5.3.3.9 Device
      • 5.3.3.10 Mode
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 Form
      • 5.4.1.8 End User
      • 5.4.1.9 Device
      • 5.4.1.10 Mode
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 Form
      • 5.4.2.8 End User
      • 5.4.2.9 Device
      • 5.4.2.10 Mode
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 Form
      • 5.4.3.8 End User
      • 5.4.3.9 Device
      • 5.4.3.10 Mode
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 Form
      • 5.4.4.8 End User
      • 5.4.4.9 Device
      • 5.4.4.10 Mode
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 Form
      • 5.4.5.8 End User
      • 5.4.5.9 Device
      • 5.4.5.10 Mode
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 Form
      • 5.4.6.8 End User
      • 5.4.6.9 Device
      • 5.4.6.10 Mode
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Component
      • 5.4.7.6 Application
      • 5.4.7.7 Form
      • 5.4.7.8 End User
      • 5.4.7.9 Device
      • 5.4.7.10 Mode
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 Form
      • 5.5.1.8 End User
      • 5.5.1.9 Device
      • 5.5.1.10 Mode
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 Form
      • 5.5.2.8 End User
      • 5.5.2.9 Device
      • 5.5.2.10 Mode
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 Form
      • 5.5.3.8 End User
      • 5.5.3.9 Device
      • 5.5.3.10 Mode
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 Form
      • 5.5.4.8 End User
      • 5.5.4.9 Device
      • 5.5.4.10 Mode
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 Form
      • 5.5.5.8 End User
      • 5.5.5.9 Device
      • 5.5.5.10 Mode
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Component
      • 5.5.6.6 Application
      • 5.5.6.7 Form
      • 5.5.6.8 End User
      • 5.5.6.9 Device
      • 5.5.6.10 Mode
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 Form
      • 5.6.1.8 End User
      • 5.6.1.9 Device
      • 5.6.1.10 Mode
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 Form
      • 5.6.2.8 End User
      • 5.6.2.9 Device
      • 5.6.2.10 Mode
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 Form
      • 5.6.3.8 End User
      • 5.6.3.9 Device
      • 5.6.3.10 Mode
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 Form
      • 5.6.4.8 End User
      • 5.6.4.9 Device
      • 5.6.4.10 Mode
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Component
      • 5.6.5.6 Application
      • 5.6.5.7 Form
      • 5.6.5.8 End User
      • 5.6.5.9 Device
      • 5.6.5.10 Mode

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Orexigen Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Vivus
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Arena Pharmaceuticals
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Zafgen
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Rhythm Pharmaceuticals
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Novo Nordisk
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Gelesis
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Eisai Co Ltd
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Alizyme Therapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 NeuroSearch
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Sorrento Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Amgen
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Allergan
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Saniona
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 8i Ventures
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us